Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization (2016 - 2026)

Krystal Biotech's Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $33.8 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 39.13% to $33.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $33.8 million, a 39.13% increase, with the full-year FY2025 number at $31.3 million, up 42.71% from a year prior.
  • Accumulated Depreciation & Amortization hit $33.8 million in Q1 2026 for Krystal Biotech, up from $31.3 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for KRYS hit a ceiling of $33.8 million in Q1 2026 and a floor of $4.1 million in Q4 2022.
  • Historically, Accumulated Depreciation & Amortization has averaged $16.5 million across 5 years, with a median of $15.1 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 216.33% in 2023 and later skyrocketed 39.13% in 2026.
  • Tracing KRYS's Accumulated Depreciation & Amortization over 5 years: stood at $4.1 million in 2022, then soared by 216.33% to $12.8 million in 2023, then surged by 70.88% to $21.9 million in 2024, then surged by 42.71% to $31.3 million in 2025, then rose by 7.96% to $33.8 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for KRYS at $33.8 million in Q1 2026, $31.3 million in Q4 2025, and $29.2 million in Q3 2025.